---
title: "Weekly Recap | AstraZeneca +1.47%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301464789.md"
description: "AstraZeneca (AZN) rose 1.47% this week to close at $159.20, outpacing the S&P 500 by about 0.32 percentage points. The stock opened Monday at $156.76, dipped to a weekly low of $154.81, then recovered to a weekly high of $161.29 on Wednesday before easing into the weekend. Trading was relatively thin, with daily volume averaging about 16.7% below its 60-day median."
datetime: "2026-10-10T06:08:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301464789.md)
  - [en](https://longbridge.com/en/news/301464789.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301464789.md)
generator: "portal-rs"
---

# Weekly Recap | AstraZeneca +1.47%, most brokers rate it buy

## The Week

AstraZeneca (AZN) rose 1.47% this week to close at $159.20, outpacing the S&P 500 by about 0.32 percentage points. The stock opened Monday at $156.76, dipped to a weekly low of $154.81, then recovered to a weekly high of $161.29 on Wednesday before easing into the weekend. Trading was relatively thin, with daily volume averaging about 16.7% below its 60-day median.

## Key Events

The week’s main thread ran through R&D and pipeline news. On Monday, AZN completed a $2 billion equity investment in Summit Therapeutics and opened a new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts, underscoring its push into US research capabilities. On the product side, ETCAMAH (camizestrant) drew multiple updates: DelveInsight noted its approval should accelerate oral SERD adoption, and Guardant Health announced European approval of Guardant360 CDx as a companion diagnostic. Alexion also presented Phase III HICKORY data for efzimfotase alfa in hypophosphatasia at ASBMR 2026. The flow of news was front-loaded from Monday to Thursday, while the stock’s move peaked midweek and faded.

## Analyst Ratings

Among 12 institutions covering the stock, 7 rate it buy, 3 overweight, 1 hold and 1 sell, putting 10 in the buy-or-overweight camp. The consensus rating is buy, with a consensus target of $206.99, roughly 30.0% above the latest price of $159.20. Individual targets range from $158.00 to $240.00, a wide spread that points to lingering disagreement on valuation. The stock ranks 31st within a 203-name pharmaceutical peer group.

## The Week Ahead

Next week brings a heavy macro calendar, with US CPI and core CPI due on Wednesday, 14 October. Those prints will shape rate expectations and broader risk appetite. The bigger company-specific event lands on 30 October, when AZN reports fiscal Q3 2026 results before the open, with consensus estimates around $1.1457 in EPS and $16 billion in revenue. Whether this week’s R&D and pipeline momentum translates into quantifiable financials will be the key test for the stock.

## In Short

AZN edged higher this week against a busy news flow, but money flows sent a mixed signal: on the latest trading day, large-lot flows were net sellers while small and medium orders were net buyers, suggesting institutional hesitation after the midweek rally. Ratings skew positive, but the wide target range and mid-tier industry ranking show no settled view on valuation. The market now looks to the Q3 report to validate the R&D narrative, with CPI as the macro wildcard.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

- [AstraZeneca Gets U.S. Approval for Hypertension Drug](https://longbridge.com/en/news/286724028.md)
- [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md)
- [Warren Buffett's Successor, Greg Abel, Just Went Shopping in the Tech Sector Again!](https://longbridge.com/en/news/302535520.md)
- [Oracle Corporation $ORCL Stock: Quadrant Capital Group LLC Decreases Position](https://longbridge.com/en/news/302555433.md)
- [Rocket Lab Just Had Another Setback. Here’s Why I’m Finally Buying the Stock Anyway](https://longbridge.com/en/news/302545565.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**